查询词典 R

The invention relates to a method for the extraction of keratin from dead animal skins, characterised in the treatment of dead animal skins with a substance of general formula, or at least one corresponding alkali metal, earth alkali metal, ammonium, or phosphonium salt, the variables having the following definitions: R, R = together or independently, H, C6-C14 aryl, C1-C12 alkyl, unsubstituted or substituted with one or several SH or OH groups, R, R = together or independently, H, C6-C14 aryl, C1-C12 alkyl, unsubstituted or substituted with one or several SH or OH groups, whereby at least one of R or R is not H, or R and R are not H and two vicinal groups of R to R together may be C3-C10 alkylene, R = H, C1-C12 alkyl, H-C=O or C1-C4-Alkyl-C=O, X, X, X and X = OH, SH or NHR, whereby where Rto R contains at least one sulphur atom, at least one of X to X = SH and where R to R contains no sulphur atom, at least two of X to X= SH.

本发明涉及一种从死亡动物原皮中除去角质的方法，其特征在于用通式I的物质或至少一种对应的碱金属盐、碱土金属盐、铵盐或∴盐处理死亡动物原皮，式I中各变量定义如下：R 1 和R 4 相同或不同且选自氢、C 6 -C 14 芳基和C 1 -C 12 烷基，其未被取代或被一个或多个SH或OH基团取代；R 2 和R 3 相同或不同且选自氢、C 6 -C 14 芳基和C 1 -C 12 烷基，其未被取代或被一个或多个SH或OH基团取代，其中至少一个基团R 2 或R 3 不为氢，或R 1 和R 4 不为氢，且两个相邻基团R 1 -R 4 可以一起为C 3 -C 10 亚烷基；R 5 选自氢、C 1 -C 12 烷基、H-C＝O或C 1 -C 4 烷基-C＝O；X 1 、X 2 、X 3 和X 4 选自OH、SH和NHR 5 ，其中若R 1 -R 4 含有至少一个硫原子，则至少一个基团X 1 -X 4 为SH，以及若R 1 -R 4 不含硫原子，则至少两个基团X 1 -X 4 为SH。

Soc _RR is a injective left R-module.(4) Soc _RR is a left self-injective ring.|Theorem 4.2.9 Let R be a commutative notherian ring, then the following are equivalent:(1) R is a FS-ring.(2) R is a PS-ring.(3) Every minimal ideal of R is injective.(4) Every minimal ideal of R is p-injective.

定理4.2.9若R是交换的Noethe(来源：Aae0eBe0C论文网www.abclunwen.com)r环，则以下条件等价：R是FS-环；R是PS-环；R的每个极小理想都是内射的；R的每个极小理想都是p-内射的；R是IS-环；R的每个极小理想都是投射的；R的每个极小理想都是平坦的。

If R satisfies =0 for any elements x ,y in R then ⑴when k =1, R is commutative;⑵when R has the unity, R is commutative;⑶when R has at least one right regular element and f 2 (t 1,t2) has no terms with degree1 such that Fn= F then R iscommutative when R has at least one right regular element. Here we would like to point out that the above results generalized the results of Fu changlin ,moreover generalized some results of other references . This results enriched the commutative conditions of any ring.

若任取R 中元x， y均有=0 那么⑴k =1时R 为交换环；⑵R 有单位元时R 为交换环；⑶f_2 (t_1，t_2)中t_2的次数不小于k -1且R 中至少有一个右正则元时R 为交换环。

Results Two new characterizations of regular rings are given.(1) If R is a left SF'-ring and R/Z is reduced, then R is strongly regular;(2) R is strongly regular if and only if R is a left SF'-ring whose every idempotent element of R is left semi-center and is LANE-ring.

结果 得到了SF'-环是强正则环的两个充要条件：(1)R是左SF'-环，如果R/Z是约化的，则R是强正则环；(2)R是强正则环当且仅当R是满足幂等元左半中心的左SF'-环，且R是LANE-环。

The first chapter, main instead " duo-ring " condition of " every maximal left ideal is GW-ideal " condition,study strongly regularities of GP-V-ring on this condition.lt is shown that (1) R is strongly regular iff R is left GP-V-ring whose maximal left ideals are GW-ideal.(2)R is strongly regular iff R is left GP-V-ring whose maximal right ideals are GW-ideal. The second chapter, generalize some results of GP-V-ring to GP-V-ring, discuss regularity of GP-V-ring.It is shown that (1) R is left self-injective regular with non-zero socle iff R is left GP-V -ring with Soc = Soc and R contains an injective maximal left ideal.(2)R is regular ring and every maximal essential left ideal is ideal iff R is left GP-injective left GP-V -ring and every maximal essential left ideal is ideal.

第一章主要将"duo-环"条件替换成"每一极大左理想是GW-理想"条件，研究在此条件下，GP-V-环的强正则性，证明了：(1)R是强正则环当且仅当R是左GP-V-环且R的每一极大左理想是广义弱理想；(2)R是强正则环当且仅当R是左GP-V-环且R的每一极大右理想是广义弱理想，第二章，主要将GP-V-环上一些结果推广到GP-V′-环上，讨论GP-V′-环的正则性，证明了：(1)R是左自内射正则环且Soc≠0当且仅当R是包含内射极大左理想的GP-V′-环，且Soc=Soc；(2)R是正则环且每一极大本质左理想是理想当且仅当R是左GP-内射的左GP-V′-环且每一极大本质左理想是理想。

This invention provides compounds of Formula; wherein: R is a moiety selected from the group: and n is an integer of 1 or 2; R is selected from hydrogen, amino,-NRR, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted, halogen, and a 5 to 10 membered heteroaryl ring optionally substituted, having 1 to 4 heteroatoms independently selected from N, O and S; R is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen; R is H, alkyl of 1 to 12 carbon atoms optionally substituted, cycloalkyl of 3 to 8 carbon atoms, bicycloalkyl of 5 to 10 carbon atoms or aralkyl optionally substituted; R is OH or -OH; R and R are each independently H or alkyl of 1 to 12 carbon atoms or when optionally taken together with the nitrogen atom to which each is attached form a 3 to 8 membered saturated heterocyclyl ring; R is alkyl of 1 to 12 carbon atoms optionally substituted; or a tautomer or pharmaceutically acceptable salts thereof.

本发明提供式的化合物；其中：R 1 为选自基团和的部分；n为整数1或2；R 2 选自氢、氨基、-NR 6 R 7 、具有1到12个碳原子的视情况经取代的烷基、具有6个、10个或14个碳原子的视情况经取代的芳基、具有2到12个碳原子的视情况经取代的烯基、具有2到12个碳原子的视情况经取代的炔基、卤素和具有1到4个独立地选自N、O和S的杂原子的视情况经取代的5元到10元杂芳基环；R 3 选自氢、具有1到12个碳原子的视情况经取代的烷基、具有6个、10个或14个碳原子的视情况经取代的芳基、具有2到12个碳原子的视情况经取代的烯基、乙烯基、具有2到12个碳原子的视情况经取代的炔基和卤素；R 4 为H、具有1到12个碳原子的视情况经取代的烷基、具有3到8个碳原子的环烷基、具有5到10个碳原子的双环烷基或视情况经取代的芳烷基；R 5 为OH或-OH 8 ；R 6 和R 7 各自独立地为H或具有1到12个碳原子的烷基，或当视情况与其所连接的氮原子连接在一起时形成3元到8元饱和杂环基环；R 8 为具有1到12个碳原子的视情况经取代的烷基；或其互变异构体或医药学上可接受的盐。

The present invention relates to compounds of formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkyl substituted by halogen; R is hydrogen or halogen; or R and R are together with the carbon atom to which they are attached -CH=CH-CH=CH-; R is hydrogen, lower alkyl, phenyl optionally substituted by halogen, or is hetaryl, optionally substituted by lower alkyl; R is hydrogen, lower alkyl, phenyl, benzyl, lower alkenyl, lower alkoxy, phenyloxy, benzyloxy, S-lower alkyl, halogen, CN, lower alkyl substituted by halogen or O-lower alkyl substituted by halogen; R is hydrogen or lower alkyl, aryl is phenyl or naphthyl; n is 1, 2 or 3; m is 1 or 2; and pharmaceutically acceptable acid addition salts and tautomeric forms thereof.

本发明涉及式化合物及其可药用的酸加成盐和互变异构形式，其中R 1 是氢、低级烷基、低级烷氧基、卤素或被卤素取代的低级烷基；R是氢或卤素；或R 1 和R与它们连接的碳原子一起是-CH＝CH-CH＝CH-；R 2 是氢、低级烷基、任选被卤素取代的苯基或者是任选被低级烷基取代的杂芳基；R 3 是氢、低级烷基、苯基、苄基、低级链烯基、低级烷氧基、苯氧基、苄氧基、S-低级烷基、卤素、CN、被卤素取代的低级烷基或被卤素取代的O-低级烷基；R 4 是氢或低级烷基，芳基是苯基或萘基；n是1、2或3；m是1或2。

Wherein X is an oxygen atom or a sulfur atom; C*, C** and C*** are asymmetric carbons; R 1 , R 2 , R 4 , R 5 , R 8 , R 9 and R 10 are each a lower alkyl group optionally having substituent and the like, or R 4 and R 5 and the like in combination optionally form a homocyclic ring optionally having substituent and the like; R 3 is an aryl group optionally having substituent and the like; R 6 and R 7 are each a hydrogen atom and the like; Nu is -CR 16 (COR 17 )(COR 18 ) wherein R 16 , R 17 and R 18 are each a lower alkyl group optionally having substituent and the like, and the like; and EWG is an electron withdrawing group.

通式中，X代表氧或硫；C *、C **和C ***分别表示不对称碳；R 1 、R 2 、R 4 、R 5 、R 8 、R 9 和R 10 分别代表任选取代的低级烷基等，条件是例如R 4 和R 5 可以相互结合形成任选取代的同素环等；R 3 代表任选取代的芳基等；R 6 和R 7 分别代表氢原子等；Nu表示-CR 16 (COR 17 )(COR 18 )(其中R 16 、R 17 和R 18 分别代表任选取代的低级烷基等)等；并且EWG表示吸电子基团。

This invention pertains to compounds of Formula I, their N-oxides and suitable salts wherein A is O or S; G is a 5- or 6-membered heteroaromatic ring or a 5- or 6-membered nonaromatic heterocyclic ring optionally including one or two ring members selected from the group consisting of C, SO or S2, each ring optionally substituted with from one to four R; each J is independently a phenyl ring, a 5- or 6-membered heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused carbobicyclic or heterobicyclic ring system, wherein each ring or ring system is optionally substituted with from one to four R; and R, R, R, R and n are as defined in the disclosure.

本发明涉及式I的化合物、其N-氧化物和适当盐，其中A是O或S；G是任选地包含一个或两个独立选自C、SO或S 2 的环成员的5-或6-员杂芳环或5-或6-员非芳族杂环，各环任选地被1-4个R 2 取代；各J独立地是苯环，5-或6-员杂芳环或芳族8-，9-或10-员稠合的碳二环或杂二环系，其中各环或环系任选地被1-4个R 3 取代；R 1 ，R 2 ，R 3 ，R 4 和n如说明书中定义。

The nonobvious relation is between the register state R of the original program and the location state R′ of the transformed program. Given that each pseudo-register r is mapped to the location j, we could naively require that R = R′j(r for all r.

原始程序的寄存器状态R和变换后程序的存储状态R′之间的关系并不那么明显，假定每个伪寄存器r映射到分配单元j，我们可以简单地要求对所有r有R = R′j

In the United States, chronic alcoholism and hepatitis C are the most common ones.

在美国，慢性酒精中毒，肝炎是最常见的。

If you have any questions, you can contact me anytime.

如果有任何问题，你可以随时联系我。